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Abstract 
Background: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease 
respond to infliximab treatment. The ability or inability to respond seems to persist over time. Biological 
characteristics and/or genetic background can influence the response to treatment. The aim was to assess the 
value of C-reactive protein and TNF-α serum levels before treatment as well as the TNF -308 gene 
polymorphism in the prediction of response to infliximab treatment in Crohn disease. Methods: Two-hundred-
and-twenty-six Crohn disease patients treated in the setting of an expanded access programme to infliximab in 
Belgium were studied. There were 136 refractory luminal diseases and 90 refractory fistulizing diseases. 
Luminal diseases were treated with one single infusion; fistulizing diseases with three infusions at weeks 0,2 and 
6. A clinical response to treatment was defined as either a Crohn disease activity index <150 (complete) or a 
drop of 70 points (partial) at week 4, for luminal disease, and as either complete fistula healing (complete) or a 
decrease of at least 50% of the number of draining fistulas on two consecutive visits between weeks 0 and 18, for 
fistulizing disease. CRP and serum TNF-α levels were measured at week 0 before treatment and were compared 
between responders and non-responders. Patients were genotyped for the -308 TNF gene polymorphism, and 
allelic as well as genotype frequencies were compared between responders and non-responders. Results: There 
were 73.2% responders (46.4% complete and 26.8% partial) and 26.8% non-responders. Response rates were 
similar in luminal and fistulizing diseases. CRP level before treatment was significantly higher in responders 
than in non-responders (16.8 mg/l (5-160) versus 9.6mg/l (5-143); P = 0.02). Furthermore, response rate was 
significantly higher in patients with elevated CRP (>5 mg/l) than in patients with a normal CRP value (<5mg/l) 
before treatment (76% versus 46%; P = 0.004; OR: 0.26 (0.11-0.63)). Allelic and genotype frequencies for -308 
TNF gene polymorphism were not significantly different between responders and non-responders - with the 
exception of a slightly higher TNF2 frequency in non-responders in luminal disease (22.1 % versus 11.6%; P = 
0.04). However, this was not associated with a significant difference in genotype frequencies. Conclusion: A 
positive clinical response to infliximab was associated with a higher CRP level before treatment in our 
population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. 
We therefore suggest that CRP level may help to identify better candidates for infliximab treatment. 
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Infliximab has shown a dramatic efficacy in both refractory luminal and fistulizing Crohn disease (1,2). What is 
impressive is not the percentage of response to this treatment, but rather the way the patients respond: quickly, 
with a parallel improvement in their quality of life (1,2) and with a scaring of the lesions at endoscopy (3,4) and 
histology (4,5). Such a dramatic response is observed in one-third of patients, while another third may present a 
partial response (1,2). Obviously, because of the cost and the possible side effects of this new biological therapy, 
prognostic factors for the response to infliximab would be most welcome. Furthermore, the clinical impression, 
also confirmed by biological and histological parameters, that we can define responding and non-responding 
patients to the drug is another argument for the need to search for prognostic markers. 
The clinical trials searching for prognostic factors such as the epidemiological and clinical characteristics of 
patients have not yet disclosed any relevant marker (1,2). More specific research should be based on the 
mechanism of action of infliximab. So far  this is only partly understood (6,7). Infliximab blocks soluble TNF-α 
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and thus TNF-driven inflammation. The central role of TNF-α in the inflammatory process characterizing Crohn 
disease has been well documented (8-12). One could thus speculate that the response to infliximab may depend 
on the intensity of this TNF-driven inflammation, an absence of response being due either to an excess of 
inflammation insufficiently controlled by infliximab or to another type of inflammation not dependent on TNF-α. 
In this perspective, CRP levels can be considered as a good sign of systemic inflammation in Crohn disease (14-
16), and systemic TNF-α levels may indicate the implication of TNF-α in the inflammatory process. Another 
important factor to take into account is that ability/inability to respond to infliximab is something that seems to 
persist over time (17). Therefore a genetic predisposition may well be involved in this ability to respond. Several 
polymorphisms have been described in the TNF gene (18-21). Among them a single base pair substitution at 
position -308 in the promoter region of the gene has been the most studied (19). The less frequent allele TNF2 of 
this polymorphism has been associated with an increased capacity of TNF transcription and production in several 
in vitro (22,23) and ex vivo models (24) and with diseases characterized by an increased production of TNF-α 
(25-29). Recently, we demonstrated that the TNF2 allele was associated with more severe, either steroid-
dependent or fistulizing Crohn disease (30). The aim of our work was to assess the possible association between 
serum TNF-α and CRP levels before treatment, as well as -308 TNF genotype and response to infliximab. 
 
Table I: Patient characteristics at the time of infliximab treatment 
 Luminal disease Fistulizing disease 
No. of patients 136 90 
% Male 40.4 36.7 
Age (mean ± s years) (range) 35.9 (±11.6) (17-74) 37.8 (±10.9) (16-66) 
Duration of Crohn disease (mean ± s years) 
(range) 
8.5 (±6.6) (1-30) 8.6 (±5.7) (1-30) 
Location of the disease (%) 
(ileum/ileocolon/colon) 
17.6/52.2/30.1 17.8/37.8/44.4 
CDAI (mean = s) (range) 303.8 (±100.4) (158-609) 195.7 (±113.1) (31-526) 
% on steroids 54.4 36.7 
% on 5-ASA or salazopyrine 40.4 53.3 
% on 6-mercuptopurine or azalhioprine 47.8 55.6 
% on methotrexate 8.8 1.1 
% on antibiotics 5.9 32.2 
% on cyclosporine 0 1.1 
% on FK 506 0.7 0 
s = standard deviation. 
 
Patients and Methods 
Crohn disease patients 
Two-hundred-and-twenty-six patients with Crohn disease were studied, all of them consecutively included in an 
expanded access programme of infliximab launched by Schering Plough in Belgium and Luxembourg. The 
diagnosis of Crohn disease was based on clinical, radiological and histological data in accordance with standard 
criteria. To be included in the expanded access programme the patients had to be between 18 and 65 years of 
age, adopt adequate birth control measures, give informed consent and have one of the following specific 
inclusion criteria: (1) to have single or multiple enterocutaneous draining fistula(e) as a complication of Crohn 
disease (including external and internal) resistant to conventional treatment for at least 3 months, (2) to have 
moderate to severe active Crohn disease of at least 6 months' duration, with colitis, ileitis or ileocolitis confirmed 
by radiography or endoscopy and refractory or dependent on oral corticosteroid therapy (>8 mg/day prednisone 
equivalent). These patients had to have been already treated, intolerant or non-responding to more classical 
immunosuppressants (azathioprine, 6-mercaptopurine or methotrexate). 
The clinical characteristics of the patients are given in Table I. There were two subgroups of patients: 136 
patients with active luminal (non-fistulizing) disease and 90 patients with fistulizing disease. Luminal Crohn 
disease patients were treated with a single infusion of infliximab (5 mg/kg). Before treatment, a blood sample 
and a serum sample were harvested for DNA extraction and serum TNF-α measurement, respectively. These 
patients were prospectively followed for 12 weeks with a physical examination, Crohn disease activity index 
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(31) (CDAI) calculation, CRP measurement at weeks 0,4,8 and 12. According to Targan et al. (I), they were 
considered as complete responders or partial responders in the case of a decrease of CDAI below 150 or a 
decrease of 70 points in CDAI, respectively, after 4 weeks. Patients with fistulizing disease were treated with 
three consecutive infusions (5 mg/kg) at weeks 0, 2 and 6. Before treatment blood and serum samples were 
harvested for DNA extraction and serum TNF-α measurement, respectively. These patients were prospectively 
followed up for 18 weeks with physical examination, CDAI calculation and CRP measurement at weeks 0, 2,6, 
10, 14 and 18. According to Present et al. (2), they were considered as complete responders and partial 
responders in the case of complete fistulas healing and a decrease in 50% of the number of draining fistulas at 
two consecutive visits, respectively. Ethical approval for this genetic study was given by the Ethics Committee 
of the Faculty of Medicine of Liege in March 1995. All the patients gave their informed consent specifically for 
the genetic study. 
 
Table II: CRP levels (mg/l) expressed as median and range before infliximab treatment according to response to 
treatment 
 Responders Non-responders 
Whole group of patients (109 responders/44 non-responders) 16.8 (5-160) 9.6 (5-143.5)* 
Luminal Crohn disease (60 responders/25 non-responders) 16.5 (5-160) 11 (5-143.5) 
Fistulizing Crohn disease (49 responders/19 non-responders) 16.8 (5-134) 8.1 (5-39.5) 
* P = 0.02. 
 
Controls 
One-hundred-and-twenty-eight unrelated healthy European Caucasians who served as controls for the 
genotyping were either hospital workers or prospective blood donors. None had a personal or familial history of 
inflammatory bowel disease. 
DNA extraction 
Genomic DNA was extracted from 10 ml venous blood using a modified salting out technique (32) and re-
suspended in sterile distilled water at a final concentration of 0.1-1.0 µg/µl, before use. 
TNF -308 SBP substitution 
The substitution was studied either by a polymerase chain reaction involving primers specific for each allele of 
the G to A polymorphism at residue -308, as previously described (33), or by PCR followed by NCO1 digestion. 
After amplification or digestion, DNA samples were eleclrophoresced in 1% (allele specific PCR) or 2% (PCR 
and NCO1 digestion) agarose gels containing ethidium bromide, and visualized under ultraviolet light. 
Measurement of TNF-α serum levels 
TNF-α serum level was measured on the serum samples harvested at week 0 before infliximab treatment. It was 
measured in duplicate using commercial EASIA (Biosources, Europe) in accordance with the manufacturer's 
indications. The level of TNF-α detection was 10 pg/ml. 
Statistics 
For CRP and TNF-α serum levels, the values below the detection threshold were all put at the threshold level (5 
mg/l for CRP and 10 pg/ml for TNF-α). CRP and TNF-α serum levels were expressed as median and range. 
Comparison between CRP levels before and after infliximab treatment was made using a paired non-parametric 
test (Wilcoxon signed rank test). 
CRP and TNF-α levels before treatment were compared in responders and non-responders using the Mann-
Whitney Utest. Furthermore, an optimal discriminant value between responders and non-responders was sought 
by logistic procedure and ROC curve. The proportions of responders in groups according to this optimal 
discriminant value were compared using a Fisher exact test, with calculation of the odds ratio. 
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Allelic and genotype frequencies for -308 TNF gene polymorphism were compared between responders and non-
responders using the Fisher exact test, with calculation of the odds ratio. Level of significance for all these tests 
was P < 0.05. 
Results 
Clinical and biological response to infliximab 
Overall, there were 220/226 patients evaluable for the response to infliximab treatment: 102 were complete 
responders (46.4%), 59 were partial responders (26.8%) and 59 were non-responders (26.8%). Among the 
luminal Crohn disease patients, there were 57/133 (42.9%) complete responders, 42/133 (31.6%) partial 
responders and 34/133 (25.6%) non-responders. Among the fistulizing Crohn disease patients, there were 45/87 
(51.7%) complete responders, 17/87 (19.5%) partial responders and 25/87 (28.7%) non-responders. 
The clinical response was associated with a significant decrease in CRP in the responder group (16.5 mg/l (5-
160) at week 0 versus 5 mg/l (5-54) at week 4 in luminal Crohn disease; P < 0.0001; 19.4 mg/l (5-134) at week 0 
versus 5 mg/l (5-79.6) at week 10 in fistulizing Crohn disease; P < 0.0001) which was not present in non-
responders (5 mg/l (5-110) at week 0 versus 7 mg/l (5-60.9) at week 4 in luminal Crohn disease: NS; 8.1 mg/l (5-
39.5) at week 0 versus 7 mg/l (5-64) at week 10 in fistulizing Crohn disease; NS). 
CRP level before infliximab treatment 
When comparing CRP levels before treatment in the whole group of patients, we found significantly higher 
levels in responders than in non-responders (Table II). When looking separately at luminal and fistulizing 
disease. CRP levels were still higher in responders than in non-responders, but without reaching the level of 
significance. When studying subgroups of patients according to the location of the disease or to the use of 
immunosuppressives, a higher CRP level was found in responders than in non-responders in all subgroups, but 
the difference was significant only in colonic disease (22.0 mg/l (5-160) versus 8.5 mg/l (5-144); P = 0.03). 
When grouping patients according to their baseline CRP value in two subgroups: one with normal CRP value 
(<5mg/l) and the second with elevated CRP value (>5 mg/l), there were 12/26 (46%) responders in the first one 
and 97/127 (76%) in the second one (P = 0.004; OR = 0.26 (95% CI: 0.11-0.63). Logistic procedure and ROC 
curve disclosed no better discriminant level of CRP. This discrimination on the basis of a CRP level at 5 mg/l 
was more prominent in luminal disease (6/15 (40%) versus 54/70 (77%); P = 0.009; OR = 0.20 (95% CI: 0.06-
0.64) than in fistulizing disease (6/11 (54%) versus 43/57 (75%); P = 0.26). 
 
Table III: TNF-α levels (pg/ml) expressed as median and range before infliximab treatment according to 
response to treatment 
 Responders Non-responders 
Whole group of patients (109 responders/44 non-responders) 14 (10-314) 14 (10-90.9) 
Luminal Crohn's disease (60 responders/25 non-responders) 15.2 (10-314) 10 (10-32.6)* 
Fistulizing Crohn's disease (49 responders/19 non-responders) 13 (10-242) 21.6 (10-90.9) 
*P=0.06. 
Table IV: Allelic and genotype frequencies (%) for -308 TNF gene polymorphism according to response to 
infliximab treatment 
 TNF1 TNF2 TNF1/TNF1 TNF1/TNF2 TNF2/TNF2 
Responders (n = 158) 85.8 14.2 73.4 24.7 1.9 
Non-responders (n = 56) 78.6 21.4 62.5 32.1 5.4 
 
Serum TNF-α level before infliximab treatment (Table III) 
When comparing TNF-α levels between responders and non-responders in the whole population, we found no 
significant difference. However, when looking separately at luminal disease, there was a trend toward a higher 
TNF-α (P = 0.06) serum level before treatment in responders. There was no significant difference in fistulizing 
Crohn disease studied separately. When studying subgroups of patients according to the location of the disease 
or to the use or not of immunosuppressives, there was no significant difference between responders and non-
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responders. When grouping patients according to their baseline TNF-α level (< 10 pg/ml or > 10 pg/ml) there 
was no significant difference in response rate either in the whole group of patients or in luminal or fistulizing 
disease separately. Logistic procedure and ROC curve found no significant discriminant level for TNF-α. 
-308 TNF genotyping 
Genotyping for -308 TNF polymorphism was successful in 220/226 patients. Allelic frequencies for the -308 
TNF genotyping were 83.9% for TNF1 and 16.1% for TNF2. This was not significantly different from allelic 
frequencies in controls (85.2% and 14.8% for TNF1 and TNF2, respectively). 
In 214 patients, we had both successful genotyping and evaluable clinical response. Allelic and genotype 
frequencies according to the response to infliximab are given in Table IV. There was no significant difference 
between responders (complete and partial) and non-responders. There was no significant difference either when 
considering complete responders only, compared to non-responders (TNF2 allelic frequencies: 16.5% and 21.4% 
in complete responders and non-responders, respectively; NS). 
When looking separately at fistulizing Crohn disease, there was no significant difference between responders and 
non-responders (TNF2 frequency was 18.6% and 20.5% in responders and non-responders, respectively; NS). 
Allelic and genotype frequencies in luminal Crohn disease are given in Table V. There was a slight significant 
increase of TNF2 in non-responders (P = 0.04), but there was no significant difference when comparing 
genotypes. When grouping the patients according  to location  of the disease or use of immunosuppressives, 
there was no significant difference between responders and non-responders.  
Finally, the serum TNF-α levels before treatment were not significantly different between TNF1 homozygotes 
and TNF2 carriers (10 pg/ml (10-314) versus 15.6 pg/ml (10-242); NS). 
 
Table V: Allelic and genotype frequencies (%) for -308 TNF gene polymorphism according to response to 
infliximab treatment in the subgroup of luminal Crohn disease 
 TNF1 TNF2 TNF1/TNF1 TNF1/TNF2 TNF2/TNF2 
Responders (n = 99) 88.4 11.6 77.8 21.2 1 
Non-responders (n = 34) 77.9 22.1* 64.7 26.5 8.8 
*P = 0.04. 
 
Discussion 
In this study, both biological and genetic characteristics were examined as prognostic factors for response to 
infliximab. There was a positive significant association between response to infliximab and CRP level before 
treatment. There was also a trend toward a higher TNF-α level in responders essentially in luminal Crohn 
disease, but no clinically relevant association with the -308 TNF genotype. 
The patients included in the present study were treated with infliximab in the setting of an expanded access 
programme to that treatment. The criteria of treatment in this programme were similar to those in previously 
published controlled trials (1,2). The presence of a clinical response was also determined according to previously 
published criteria (1,2). Not surprisingly, the response rate was concordant with what has been observed in 
treated patients in those controlled studies. Furthermore, as in the trial with luminal Crohn disease (1), we 
observed a significant biological response associated with the clinical response, as assessed by a decrease in CRP 
levels. In our patients, the significant biological response was also present in responding fistulizing Crohn 
disease. This associated biological response strengthens the value of our clinical evaluation. When defining the 
biological or genetic criteria that are associated with response to treatment, this is of paramount importance. 
What is striking with infliximab treatment is that, despite clinical improvement in more than two-thirds of 
patients, sometimes very impressive and dramatic, still one-fourth to one-third of patients do not respond at all to 
the treatment. Therefore, it seemed logical to isolate these non-responders as a relevant homogeneous subgroup 
of patients and to compare them to either partial or complete responders. 
The most relevant result of our work is the higher baseline CRP level in patients who respond to infliximab. It 
was possible, mainly in luminal disease, to separate patients according to baseline CRP level into two subgroups 
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with significantly different proportions of response to infliximab. At first sight, it may seem strange that some 
refractory Crohn disease patients may have low and even normal CRP levels. However, these patients were often 
already treated with multiple anti-inflammatory and immunomodulatory drugs, probably decreasing the systemic 
inflammatory reaction without completely controlling the activity of the disease. Indeed, it has been shown 
consistently that there is no perfect correlation between clinical activity indexes and biological parameters of 
inflammation in Crohn disease (34). Furthermore, in our patients who were selected for infliximab treatment on 
the basis of clinical activity assessed either by the CDAI or by the existence of refractory draining fistulae, there 
was no association between CDAI before treatment and response to treatment (data not shown). We cannot 
therefore conclude that non-responders had actually inactive disease but rather that they were patients with 
clinically active disease despite a low systemic inflammatory reaction. The mechanisms of these persistently 
active Crohn diseases without classical systemic inflammation remain unclear, but may involve other patterns of 
inflammatory and immune activation (35). Interestingly, in luminal disease, the higher CRP level in responders 
was also associated with a higher TNF-α level. Serum TNF-α level does not have a good sensitivity for gut 
inflammation. Although it is generally higher in active than in inactive disease, its correlation with clinical 
disease activity is not strong (36) despite increased local production and even clinical significance of the 
increased local production (8-10). This situation may be due to the short half-life of locally produced TNF-α 
(37). It is therefore relevant to find higher serum TNF-α levels in patients responding to infliximab because it 
may represent the tip of the iceberg of a stronger TNF-driven mucosal inflammation. The fact that this trend was 
not found in fistulizing Crohn disease may be due to a reduced extent of intestinal lesions in a large proportion of 
the patients who had mainly perianal disease in comparison with patients who had more extensive luminal 
disease. According to this, many patients with fistulizing Crohn disease had a normal CDAI before treatment, 
indicating a rather quiescent luminal disease. In these patients, the amount of TNF-α reaching blood circulation 
was probably insufficient to be detected. 
TNF-α production has been shown to depend on genetic background. In particular the -308 polymorphism in the 
promoter of the gene has been shown to influence TNF-α transcription (22). The carriage of the rarer allele of 
this polymorphism (TNF2) has been associated with a higher capacity of TNF-α production in several in vitro 
(23) and ex vivo (24) models, although no influence was found by some authors (38,39). In a previous study we 
found an increased frequency of TNF2 in severe, particularly steroid-dependent Crohn disease, although this 
subgroup of patients was only a small sample (30). However, as far as the response to infliximab is concerned, in 
the present study we did not find any association between TNF2 carriage and a positive response to infliximab 
which could have been suspected in view of the higher CRP and TNF serum levels in responders. We even 
found a lower frequency of allele TNF2 in responders in the subgroup of refractory active Crohn disease but 
without significant difference in genotype frequencies. Furthermore, we found no association between -308 TNF 
genotype and serum TNF levels in our population. These results may be interpreted either as an absence of or at 
best a weak (and insufficient to be detected) influence of this polymorphism on TNF production and circulating 
level. According to our results, -308 TNF gene polymorphism plays  no  relevant  role   in   determining  the  
response  to infliximab. Other TNF gene polymorphisms may still be involved. A recent article on a rather small 
cohort of patients suggested an association between polymorphisms in the lymphotoxin A gene (or the adjacent 
TNF region) and response to infliximab (17). However, another recent study, also in a fairly small population of 
infliximab-treated patients has not found any association between several single base pair polymorphisms as well 
as microsatellites in TNF gene and the response to infliximab (40). These results should be confirmed on a larger 
population of patients. Beside TNF other genes should also be studied. However, the choice of relevant 
candidate genes would necessitate a better understanding of the mechanism of action of infliximab, which is still 
only partly understood. Besides blockade of soluble TNF-α (41,42), infliximab also binds membrane TNF (43). 
By doing this, it may induce death of the cells expressing TNF by complement activation (43). antibody-
dependent cell-mediated cytotoxicity (43) or even induction of apoptosis (6). A recent article shedding some new 
light on the definition of response to infliximab shows that what we have been calling non-responders at 4 weeks 
may actually be short duration responders (44). In that study, almost 90% of patients were clinical and biological 
responders at 1 week, but one-third of them had a quick reactivation of TNF-α secretion and increase of NFκB in 
the mucosa associated with clinical activity. 
In conclusion, a positive response to infliximab was associated with a higher systemic inflammatory reaction as 
assessed by CRP and. to a lesser extent. TNF-α serum levels, but not with a particular genotype of -308 TNF 
gene polymorphism. Therefore, besides the clinical activity of the disease in patients considered as refractory 
Crohn disease and candidates for infliximab treatment it would be justifiable to prefer this treatment in patients 
with high systemic inflammatory reaction, in particular elevated CRP level. 
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